Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer

Triple negative breast cancer accounts for 15–20% of all breast cancer cases, but despite its lower incidence, contributes to a disproportionately higher rate of mortality. As there are currently no Food and Drug Administration-approved targeted agents for triple negative breast cancer, we embarked...

Descripción completa

Detalles Bibliográficos
Autores principales: Solzak, Jeffrey P., Atale, Rutuja V., Hancock, Bradley A., Sinn, Anthony L., Pollok, Karen E., Jones, David R., Radovich, Milan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460220/
https://www.ncbi.nlm.nih.gov/pubmed/28649657
http://dx.doi.org/10.1038/s41523-017-0016-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460220/
https://www.ncbi.nlm.nih.gov/pubmed/28649657
http://dx.doi.org/10.1038/s41523-017-0016-8

Ejemplares similares